New study offers hope for kids with peanut allergy

Peanut allergy research

A study last week in The New England Journal of Medicine suggests that exposing infants to peanuts can provide lasting protection against peanut allergy. But what about peanut-allergic children right now? They and their parents live a life of precautions — from pre-screening birthday party menus to segregation at the school lunch table — to avoid life-threatening consumption of even trace amounts of peanut.

Now, a multi-center study reports on a protocol combining the allergy medication omalizumab (Xolair) with controlled, gradually increasing peanut consumption. After 20 weeks, most initially allergic children could safely consume the equivalent of 8 to 10 peanuts at a time. Three months after stopping the medication, most had worked up to 16 to 20 peanuts.

The small boost in peanut tolerance may not seem like much, but it could mean less worry for parents who are constantly on guard for even trace amounts of the substance. Our sister blog, Vector, has more of the story.

Learn more about peanut allergy research on Vector